Atlas Trials

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Clinical trial NCT01830543 · COMPLETED

Trial details

NCT number
NCT01830543
Sponsor
Janssen Scientific Affairs, LLC
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Atrial FibrillationPercutaneous Coronary Intervention
Start date
2013-05-10
Primary completion
2016-07-28
Enrollment
2124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.